pharmaceuticals | Science and Enterprise

A new venture investment company is funding start-ups at their earliest stages, with a goal of increasing support f… https://t.co/mM44gsVcT9
about 1 day ago
New post on Science and Enterprise: Early Venture Investors Aim for Diverse Entrepreneurs https://t.co/y9tdzGJ9rP #Science #Business
about 1 day ago
Fascinating hypothesis. We wrote about this team's work in nanomedicine for crossing blood-brain barrier in October… https://t.co/ud8TGIrXt7
about 1 day ago
The Food and Drug Administration issued its standards that developers need to meet in evidence submitted for review… https://t.co/0G93MkzRwL
about 2 days ago
New post on Science and Enterprise: FDA Sets Review Criteria for Covid-19 Vaccines https://t.co/87eIr3uU3t #Science #Business
about 2 days ago

Covid-19 Dual Therapy Drug Trial Okayed

By Alan, on June 17th, 2020%

A company developing an oral drug that treats both Covid-19 infections and overactive immune system reactions received regulatory approval for a later-stage clinical trial. . . . → Read More: Covid-19 Dual Therapy Drug Trial Okayed

Engineered Immune, Stem Cells Studied for HIV Cure

By Alan, on June 17th, 2020%

Academic and industry researchers are investigating engineered immune-system cells combined with stem cells as an immunotherapy to neutralize HIV viruses and cure infections. . . . → Read More: Engineered Immune, Stem Cells Studied for HIV Cure

Partnership to Speed Covid-19 Clinical Trials

By Alan, on June 16th, 2020%

A company that aims to accelerate clinical trials is partnering with an entrepreneur and researcher to speed up the pace of new trials of Covid-19 vaccines, therapies, and diagnostics. . . . → Read More: Partnership to Speed Covid-19 Clinical Trials

Biotechs Partner on Crispr for Stem Cell Transplants

By Alan, on June 15th, 2020%

A biotechnology partnership is evaluating a synthetic antibody to make it safer for people with genetic diseases to receive gene-edited bone marrow stem-cell transplants. . . . → Read More: Biotechs Partner on Crispr for Stem Cell Transplants

Covid-19 Antibody Cocktail to Begin Clinical Trial

By Alan, on June 11th, 2020%

A combination of two synthetic antibodies, with an enhanced infection-blocking design for preventing and treating Covid-19 infections, is set to begin a clinical trial. . . . → Read More: Covid-19 Antibody Cocktail to Begin Clinical Trial

Crispr Heart Disease Start-Up Raises New $63M

By Alan, on June 11th, 2020%

A one year-old company developing a one-time gene-editing treatment for coronary artery disease is adding $63 million to its first venture funding round. . . . → Read More: Crispr Heart Disease Start-Up Raises New $63M

Cancer Drug Technology Licensed for Covid-19

By Alan, on June 10th, 2020%

A biotechnology company is licensing medical research discoveries from university labs first designed for treating cancer as a potential Covid-19 therapy. . . . → Read More: Cancer Drug Technology Licensed for Covid-19

Foundations Back ALS Biomarker Study

By Alan, on June 9th, 2020%

Two organizations supporting research on amyotrophic lateral sclerosis or ALS are funding a study of changes to chemical indicators in the body responding to ALS drugs. . . . → Read More: Foundations Back ALS Biomarker Study

Covid-19 Vaccine for Lower-Income Regions Underway

By Alan, on June 8th, 2020%

Researchers in the U.K. designed a vaccine to prevent Covid-19 infections and is starting an enterprise to make it available to lower-income countries. . . . → Read More: Covid-19 Vaccine for Lower-Income Regions Underway

Infographic – High Hopes for Covid-19 Therapy, Vaccine

By Alan, on June 6th, 2020%

Sizeable majorities of Americans expect to see treatments and a vaccine for Covid-19 in the next 12 months, but also another outbreak of the disease. . . . → Read More: Infographic – High Hopes for Covid-19 Therapy, Vaccine

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise